

Pajaree Chariyavilaskul

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7706062/publications.pdf>

Version: 2024-02-01

36
papers

325
citations

933447

10
h-index

888059

17
g-index

37
all docs

37
docs citations

37
times ranked

652
citing authors

#	ARTICLE	IF	CITATIONS
1	Host genetic factors of COVID-19 susceptibility and disease severity in a Thai population. <i>Journal of Human Genetics</i> , 2022, 67, 295-301.	2.3	15
2	Comparative efficacy between hemodialysis using super high-flux dialyzer with hemoperfusion and high-volume postdilution online hemodiafiltration in removing protein bound and middle molecule uremic toxins: A crossover randomized controlled trial. <i>Artificial Organs</i> , 2022, 46, 775-785.	1.9	4
3	The sterility, stability and efficacy of repackaged ziv-aflibercept for intravitreal administration. <i>Scientific Reports</i> , 2022, 12, 2971.	3.3	1
4	Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia. <i>Pharmacogenomics and Personalized Medicine</i> , 2022, Volume 15, 119-130.	0.7	1
5	Genotypic and phenotypic landscapes of 51 pharmacogenes derived from whole-genome sequencing in a Thai population. <i>PLoS ONE</i> , 2022, 17, e0263621.	2.5	4
6	Comparative Effectiveness between Expanded Hemodialysis (Hemodialysis Using a Medium Cut-Off) and High-Flux Hemodialysis in Removing Middle-Molecule Uremic Toxins. <i>Blood Purification</i> , 2022, 51, 923-931.	1.8	4
7	Association Between Indoxyl Sulfate and Dialysis Initiation and Cardiac Outcomes in Chronic Kidney Disease Patients. <i>International Journal of Nephrology and Renovascular Disease</i> , 2022, Volume 15, 115-126.	1.8	2
8	A simple LC-MS/MS method for pharmacokinetic study of carvedilol and 4-hydroxyphenyl carvedilol at a low dose. <i>Research in Pharmaceutical Sciences</i> , 2022, 17, 231.	1.8	2
9	Pharmacokinetics and pharmacodynamics profiles of enteric-coated mycophenolate sodium in female patients with difficult-to-treat lupus nephritis. <i>Clinical and Translational Science</i> , 2022, 15, 1776-1786.	3.1	4
10	Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection. <i>International Journal of Infectious Diseases</i> , 2022, 122, 725-732.	3.3	2
11	Super high-flux hemodialysis provides comparable effectiveness with high-volume postdilution online hemodiafiltration in removing protein-bound and middle-molecule uremic toxins: A prospective crossover randomized controlled trial. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 73-81.	0.9	12
12	Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand. <i>PLoS ONE</i> , 2021, 16, e0246864.	2.5	20
13	Pharmacokinetics and metabolomics investigation of an orally modified formula of standardized <i>Centella asiatica</i> extract in healthy volunteers. <i>Scientific Reports</i> , 2021, 11, 6850.	3.3	12
14	Influence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 915-926.	0.7	2
15	Quantification of CYP3A and Drug Transporters Activity in Healthy Young, Healthy Elderly and Chronic Kidney Disease Elderly Patients by a Microdose Cocktail Approach. <i>Frontiers in Pharmacology</i> , 2021, 12, 726669.	3.5	12
16	Protein-Bound Uremic Toxins Lowering Effect of Sevelamer in Pre-Dialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized Controlled Trial. <i>Toxins</i> , 2021, 13, 688.	3.4	1
17	SLCO1B1 and ABCG2 Gene Polymorphisms in a Thai Population. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 521-530.	0.7	3
18	CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 543-551.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Phenotype prediction and characterization of 25 pharmacogenes in Thais from whole genome sequencing for clinical implementation. <i>Scientific Reports</i> , 2020, 10, 18969.	3.3	11
20	Intraperitoneal cefazolin and ceftazidime during short-dwell exchange in peritoneal dialysis patients with peritonitis. <i>Peritoneal Dialysis International</i> , 2020, 40, 179-184.	2.3	5
21	Pharmacogene Variation in Thai <i>Plasmodium vivax</i> Relapse Patients Treated with a Combination of Primaquine and Chloroquine. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 1-12.	0.7	7
22	Greater optimisation of pharmacokinetic/pharmacodynamic parameters through a loading dose of intravenous colistin in paediatric patients. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105940.	2.5	6
23	Development and validation of an ultra-performance liquid chromatography mass spectrometry/mass spectrometry method for simultaneous quantification of total and free mycophenolic acid and its metabolites in human plasma. <i>Journal of Advanced Pharmaceutical Technology and Research</i> , 2020, 11, 207.	1.0	2
24	Safety and Pharmacokinetics of Standardized Extract of <i>Centella asiatica</i> (ECa 233) Capsules in Healthy Thai Volunteers: A Phase 1 Clinical Study. <i>Planta Medica</i> , 2019, 85, 483-490.	1.3	29
25	The prominent impairment of liver/intestinal cytochrome P450 and intestinal drug transporters in sepsis-induced acute kidney injury over acute and chronic renal ischemia, a mouse model comparison. <i>Renal Failure</i> , 2019, 41, 314-325.	2.1	14
26	Effect of Pomelo Juice on the Pharmacokinetics of Simvastatin, CYP3A2 Activity and Mdr1a, Mdr1b and Slc21a5 Expressions in Rats. <i>Pharmaceutical Sciences</i> , 2019, 25, 303-310.	0.2	1
27	The Cytochrome P450 3A5 Non-Expressor Kidney Allograft as a Risk Factor for Calcineurin Inhibitor Nephrotoxicity. <i>American Journal of Nephrology</i> , 2018, 47, 182-190.	3.1	9
28	Pharmacokinetic parameters of nicotine and its metabolites in Thai smokers with different CYP2A6 enzyme activity. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO1-11-16.	0.0	0
29	Short-Dwell Cycling Intraperitoneal Cefazolin plus Ceftazidime in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2017, 37, 218-224.	2.3	7
30	Bioequivalence and pharmacokinetic/pharmacodynamic correlation of clopidogrel in healthy Thai subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2017, 55, 915-922.	0.6	2
31	Pharmacokinetics and bioequivalence of a pregabalin 150-mg capsule in healthy Thai subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2017, 55, 811-817.	0.6	1
32	Plasma Pro-Endothelin-1 Peptide Concentrations Rise in Chronic Kidney Disease and Following Selective Endothelin A Receptor Antagonism. <i>Journal of the American Heart Association</i> , 2015, 4, e001624.	3.7	16
33	In vitro anti-lithogenic activity of lime powder regimen (LPR) and the effect of LPR on urinary risk factors for kidney stone formation in healthy volunteers. <i>Urolithiasis</i> , 2015, 43, 125-134.	2.0	10
34	Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease. <i>Journal of Lipid Research</i> , 2015, 56, 413-422.	4.2	70
35	Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 431-436.	0.6	2
36	Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis. <i>Lupus</i> , 2013, 22, 727-732.	1.6	28